Cowen's Line in the Sand
Executive Summary
Cowen's Dan LeMaitre, a leading device analyst, dropped coverage of Boston Scientific claiming that the company wasn't providing sufficient information for accurate valuations. The dispute calls into question an investor relations strategy one executive calls "seriously flawed."
You may also be interested in...
QUOTED. 4 March 2021. Meghan Scanlon.
Boston Scientific has agreed to pay $1.07bn to acquire Lumenis’ surgical laser business from Baring Private Equity Asia. See what Meghan Scanlon, president of Boston Scientific’s urology and pelvic health business, said about it here.
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.
US FDA Still Discussing Ideas For Pediatric Development Of COVID-19 Vaccines
J&J CEO Gorsky says the agency is working with sponsors to ensure the proper data is gathered to make the vaccine available in children.
Need a specific report? 1000+ reports available
Buy Reports